DK0639979T3 - Ligand for c-kit-receptoren og fremgangsmåde til anvendelse heraf - Google Patents

Ligand for c-kit-receptoren og fremgangsmåde til anvendelse heraf

Info

Publication number: DK0639979T3
Authority: DK; Denmark
Prior art keywords: methods; kit ligand; applicants; antagonist; purified
Prior art date: 1992-04-23

Application number

DK93910645T

Other languages

Danish (da)

English (en)

Inventor

Peter Besmer

Jochen Buck

Malcolm A S Moore

Karl Nocka

Original Assignee

Sloan Kettering Inst Cancer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-04-23

Filing date

1993-04-16

Publication date

2002-12-02

1993-04-16 Application filed by Sloan Kettering Inst Cancer filed Critical Sloan Kettering Inst Cancer

2002-12-02 Application granted granted Critical

2002-12-02 Publication of DK0639979T3 publication Critical patent/DK0639979T3/da

Links

238000000034 method Methods 0.000 title abstract 4
102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 title 1
108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 title 1
239000003446 ligand Substances 0.000 title 1
102000015215 Stem Cell Factor Human genes 0.000 abstract 10
108010039445 Stem Cell Factor Proteins 0.000 abstract 10
239000005557 antagonist Substances 0.000 abstract 2
238000002648 combination therapy Methods 0.000 abstract 2
230000003394 haemopoietic effect Effects 0.000 abstract 2
239000000203 mixture Substances 0.000 abstract 2
239000008194 pharmaceutical composition Substances 0.000 abstract 2
230000000692 anti-sense effect Effects 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
239000003937 drug carrier Substances 0.000 abstract 1
239000012634 fragment Substances 0.000 abstract 1
210000004602 germ cell Anatomy 0.000 abstract 1
210000003630 histaminocyte Anatomy 0.000 abstract 1
210000002752 melanocyte Anatomy 0.000 abstract 1
102000039446 nucleic acids Human genes 0.000 abstract 1
108020004707 nucleic acids Proteins 0.000 abstract 1
150000007523 nucleic acids Chemical class 0.000 abstract 1
229920001184 polypeptide Polymers 0.000 abstract 1
102000004196 processed proteins & peptides Human genes 0.000 abstract 1
108090000765 processed proteins & peptides Proteins 0.000 abstract 1
238000010188 recombinant method Methods 0.000 abstract 1
150000003384 small molecules Chemical class 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2006—IL-1
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/202—IL-3
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Epidemiology (AREA)
Cell Biology (AREA)
Hematology (AREA)
Genetics & Genomics (AREA)
Toxicology (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Ophthalmology & Optometry (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Virology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Dermatology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Neurosurgery (AREA)

DK93910645T 1992-04-23 1993-04-16 Ligand for c-kit-receptoren og fremgangsmåde til anvendelse heraf DK0639979T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US87396292A	1992-04-23	1992-04-23
PCT/US1993/003640 WO1993021936A1 (fr)	1992-04-23	1993-04-16	LIGAND POUR LE RECEPTEUR DE c-KIT ET PROCEDES D'UTILISATION

Publications (1)

Publication Number	Publication Date
DK0639979T3 true DK0639979T3 (da)	2002-12-02

Family

ID=25362700

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK93910645T DK0639979T3 (da)	1992-04-23	1993-04-16	Ligand for c-kit-receptoren og fremgangsmåde til anvendelse heraf

Country Status (15)

Country	Link
US (1)	US6159461A (fr)
EP (2)	EP0639979B1 (fr)
JP (1)	JP3750819B2 (fr)
KR (1)	KR100313064B1 (fr)
AT (1)	ATE206309T1 (fr)
AU (1)	AU675429B2 (fr)
CA (1)	CA2133982C (fr)
DE (1)	DE69330878T2 (fr)
DK (1)	DK0639979T3 (fr)
ES (1)	ES2168273T3 (fr)
HK (1)	HK1041205A1 (fr)
HU (1)	HU219540B (fr)
PT (1)	PT639979E (fr)
RU (1)	RU2180850C2 (fr)
WO (1)	WO1993021936A1 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6852313B1 (en)	1989-10-16	2005-02-08	Amgen Inc.	Method of stimulating growth of melanocyte cells by administering stem cell factor
US7144731B2 (en)	1989-10-16	2006-12-05	Amgen Inc.	SCF antibody compositions and methods of using the same
US20050276784A1 (en) *	1990-08-27	2005-12-15	Solan-Kettering Institute For Cancer Research	Ligand for the c-kit receptor and methods of use thereof
US5525708A (en) *	1994-03-28	1996-06-11	Cytomed, Inc.	Covalent dimer of kit ligand
DE4412794A1 (de) *	1994-04-14	1995-12-14	Univ Ludwigs Albert	Verfahren zur Herstellung von dendritischen Zellen, so erhaltene Zellen und Behälter zur Durchführung dieses Verfahrens
WO1996015230A2 (fr) *	1994-11-16	1996-05-23	Amgen Inc.	Utilisation du facteur des cellules souches et du recepteur de l'interleukine 6 soluble dans le developpement ex vivo des cellules multipotentielles hematopoietiques
US6248326B1 (en) *	1997-09-10	2001-06-19	Harry C. Blair	Regulation of osteoclast formation by inhibition of osteoblastic stem cell factor
US6599710B1 (en)	1999-03-10	2003-07-29	The General Hospital Corporation	Treatment of autoimmune disease
US7541184B2 (en)	2000-02-24	2009-06-02	Invitrogen Corporation	Activation and expansion of cells
US7572631B2 (en)	2000-02-24	2009-08-11	Invitrogen Corporation	Activation and expansion of T cells
WO2002066069A1 (fr) *	2001-02-20	2002-08-29	Kansai Technology Licensing Organization Co., Ltd.	Remedes contre l'inflammation/les maladies tumorales
CN1541113A (zh) *	2001-04-27	2004-10-27	�Ƹ��	利用激活的t细胞使抗原提呈细胞成熟
US7628988B2 (en)	2002-06-27	2009-12-08	The General Hospital Corporation	Methods and compositions for treating type 1 diabetes
US7582313B2 (en) *	2002-06-27	2009-09-01	The General Hospital Corporation	Methods of organ regeneration using Hox 11-expressing pluripotent cells
WO2004072264A2 (fr) *	2003-02-12	2004-08-26	Johns Hopkins University School Of Medicine	Determination de la destinee par hes1 dans des cellules souches et progenitrices hematopoietiques et utilisation
US20080102054A1 (en) *	2005-01-18	2008-05-01	Faustman Denise L	Compositions Containing Agm Cells And Methods Of Use Thereof
DE602005024371D1 (de)	2005-05-10	2010-12-09	Agfa Gevaert Nv	Verfahren zur Verarbeitung von Flachdruckplatten
WO2014124134A1 (fr)	2013-02-07	2014-08-14	The General Hospital Corporation	Procédés d'expansion ou de déplétion de lymphocytes t régulateurs
CN111879948A (zh)	2013-10-17	2020-11-03	综合医院公司	鉴定响应于用于自身免疫性疾病的治疗的受试者的方法以及用于治疗该疾病的组合物
RU2563235C1 (ru) *	2014-07-29	2015-09-20	Федеральное государственное бюджетное учреждение "Научный центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова" Министерства здравоохранения Российской Федерации	Способ увеличения пула стволовых клеток в организме
CA2985816A1 (fr)	2015-05-15	2016-11-24	The General Hospital Corporation	Anticorps antagonistes de la superfamille du recepteur du facteur de necrose anti-tumoral
EP3340999A4 (fr)	2015-08-28	2019-06-12	The General Hospital Corporation	Anticorps agonistes anti-récepteurs de type ii du facteur de nécrose tumorale
EP3355914B1 (fr)	2015-09-29	2024-03-06	The General Hospital Corporation	Une composition comprenant bcg pour réduire le cholesterol.
CA3253342A1 (en)	2016-05-13	2026-03-02	The General Hospital Corporation	Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
CA3109954A1 (fr)	2018-08-20	2020-02-27	The General Hospital Corporation	Polypeptides antagonistes de la superfamille des recepteurs au facteur de necrose tumorale
JP7652690B2 (ja)	2018-11-15	2025-03-27	ザジェネラルホスピタルコーポレイション	アゴニスト性腫瘍壊死因子受容体スーパーファミリーポリペプチド

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1991014757A1 (fr) *	1990-03-28	1991-10-03	Nisshin Steel Co., Ltd.	Lubrifiant pour laminage a chaud d'acier inoxydable
US5399493A (en) *	1989-06-15	1995-03-21	The Regents Of The University Of Michigan	Methods and compositions for the optimization of human hematopoietic progenitor cell cultures
DK0423980T3 (da) *	1989-10-16	2000-10-09	Amgen Inc	Stamcellefaktor
WO1992000376A1 (fr) *	1990-06-25	1992-01-09	Immunex Corporation	Facteur de croissance de mastocytes
DE4026026A1 (de) *	1990-08-17	1992-02-20	Hoechst Ag	Acylaminomethyl-phosphinsaeuren und verfahren zur herstellung von acylaminomethanphosphonsaeuren und acylaminomethyl-phosphinsaeuren
US5767074A (en) *	1990-08-27	1998-06-16	Sloan-Kettering Institute For Cancer Research	Compositions of soluble C-kit ligand and hematopoietic factors
US20030125519A1 (en) *	1990-08-27	2003-07-03	Peter Besmer	Ligand for the c-kit receptor and methods of use thereof
AU9028791A (en) *	1990-10-05	1992-04-28	President And Fellows Of Harvard College	Detection and isolation of ligands
US5409825A (en) *	1991-04-09	1995-04-25	Indiana University Foundation	Expansion of human hematopoietic progenitor cells in a liquid medium
US5199942A (en) *	1991-06-07	1993-04-06	Immunex Corporation	Method for improving autologous transplantation
US6001803A (en) *	1992-04-23	1999-12-14	Sloan-Kettering Institute For Cancer Research	Composition of c-kit ligand, GM-CSF, and TNF-α and method of use

1993
- 1993-04-16 DE DE69330878T patent/DE69330878T2/de not_active Expired - Fee Related
- 1993-04-16 AT AT93910645T patent/ATE206309T1/de not_active IP Right Cessation
- 1993-04-16 PT PT93910645T patent/PT639979E/pt unknown
- 1993-04-16 WO PCT/US1993/003640 patent/WO1993021936A1/fr not_active Ceased
- 1993-04-16 EP EP93910645A patent/EP0639979B1/fr not_active Expired - Lifetime
- 1993-04-16 DK DK93910645T patent/DK0639979T3/da active
- 1993-04-16 HU HU9403054A patent/HU219540B/hu not_active IP Right Cessation
- 1993-04-16 JP JP51932293A patent/JP3750819B2/ja not_active Expired - Fee Related
- 1993-04-16 AU AU41065/93A patent/AU675429B2/en not_active Ceased
- 1993-04-16 RU RU94046426/14A patent/RU2180850C2/ru active
- 1993-04-16 EP EP01104932A patent/EP1127577A3/fr not_active Withdrawn
- 1993-04-16 ES ES93910645T patent/ES2168273T3/es not_active Expired - Lifetime
- 1993-04-16 CA CA002133982A patent/CA2133982C/fr not_active Expired - Lifetime
1994
- 1994-10-24 KR KR1019940703793A patent/KR100313064B1/ko not_active Expired - Fee Related
1997
- 1997-07-23 US US08/898,982 patent/US6159461A/en not_active Expired - Lifetime
2002
- 2002-02-26 HK HK02101477.8A patent/HK1041205A1/en unknown

Also Published As

Publication number	Publication date
EP1127577A3 (fr)	2002-11-27
HU9403054D0 (en)	1995-02-28
EP0639979B1 (fr)	2001-10-04
ATE206309T1 (de)	2001-10-15
EP0639979A4 (fr)	1996-10-23
PT639979E (pt)	2002-03-28
WO1993021936A1 (fr)	1993-11-11
JPH07508721A (ja)	1995-09-28
RU94046426A (ru)	1997-01-10
KR950701226A (ko)	1995-03-23
RU2180850C2 (ru)	2002-03-27
KR100313064B1 (ko)	2002-04-06
CA2133982C (fr)	2008-02-12
JP3750819B2 (ja)	2006-03-01
ES2168273T3 (es)	2002-06-16
EP0639979A1 (fr)	1995-03-01
CA2133982A1 (fr)	1993-11-11
AU675429B2 (en)	1997-02-06
HK1041205A1 (en)	2002-07-05
DE69330878D1 (de)	2001-11-08
EP1127577A2 (fr)	2001-08-29
HUT70696A (en)	1995-10-30
AU4106593A (en)	1993-11-29
HU219540B (hu)	2001-05-28
DE69330878T2 (de)	2002-05-29
US6159461A (en)	2000-12-12

Publication	Publication Date	Title
HU9300541D0 (en)	1993-05-28	Ligand to receptor c-kit qnd method for its utilization
KR950701226A (ko)	1995-03-23	C-키트 수용체의 리간드 및 그의 사용방법
HUT38125A (en)	1986-04-28	Process for preparing lymphokines /cytotoxic factors/ and pharmaceutical compositions containing such active substance
DK0662827T4 (da)	2009-04-20	Terapeutiske og diagnostiske fremgangsmåder og sammensætninger baseret på Notch-proteiner og nucleinsyrer
DE69933877D1 (de)	2006-12-14	Stabiler hypoxie-induzierbarer faktor-1 alpha und verfahren zur verwendung
GEP19981289B (en)	1998-05-01	Method for Preparing Preserved Medicinal Means Containing Human Protein and Medicinal Means
ES2043890T3 (es)	1994-01-01	Nuevo uso medico.
SE9302308L (sv)	1995-01-06	Proteinberedning
CA2223433A1 (fr)	1996-12-19	Compositions renfermant la proteine ob et procedes associes
SG1893G (en)	1993-06-11	Biologically active fragments of the human antihemophilic factor and method for their preparation and pharmaceutical preparations
ATE361073T1 (de)	2007-05-15	Neue formulierungen zur transdermalen verabreichung von pergolid
DE68926679D1 (de)	1996-07-18	Physiologisch aktives polypeptid, rekombinantes plasmid, rekombinante mikrobielle zellen, medizinisches präparat sowie verfahren zur gewinnung des gereinigten polypeptids
ATE230609T1 (de)	2003-01-15	Verfahren zur behandlung von entzündungen und zusammensetzungen dafür
MY106603A (en)	1995-06-30	Treatment of genital warts with a combination of liquid nitrogen and recombinant dna human alpha interferon
ATE123941T1 (de)	1995-07-15	Verwendung von aminosäuren zum schutz von ischemischem herzgewebe und dessen metabolischer wiederherstellung.
GB1474424A (en)	1977-05-25	Pharmaceutical composition for treating diabetic ketoacidosis
AU7336687A (en)	1987-12-03	Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon
Rosti et al.	1989	In vitro and in vivo effects of recombinant interferon gamma on the growth of hematopoietic progenitor cells from patients with myelodysplastic syndrome
UA5743C2 (uk)	1994-12-29	Препарат тканинних біологічно активних речовин, який має регенаторну дію, та спосіб його одержання
MX9604455A (es)	1997-07-31	FORMULACIaN FARMACÉUTICA PARA ADMINISTRACION SUBCUT??NEA, INTRAMUSCULAR O INTRADÉRMICA DE FACTOR VIII O FACTOR IX.